TriLink BioTechnologies® and FUJIFILM Toyama Chemical Sign Non-exclusive License and Supply Agreement for CleanCap® mRNA capping technology

TriLink CleanCap® mRNA capping technology is now accessible to Fujifilm customers for non-commercial use

TOKYO, February 5, 2024 – TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and FUJIFILM Toyama Chemical, a Japanese provider of synthetic mRNA contract development and manufacturing services, have entered into a non-exclusive License and Supply Agreement for TriLink’s CleanCap® mRNA capping technology.

Aligned to the terms of the agreement, TriLink® will supply its proprietary CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG and CleanCap® AU cap analogs for use in Fujifilm’s mRNA development and manufacturing services in Japan, from pre-clinical through Phase III programs. This agreement aligns with TriLink’s objective to enable greater access to CleanCap® mRNA capping technologies. CleanCap® technology produces an optimal Cap1 structure with over 95% efficiency, creating a one-pot solution that streamlines production processes when compared to other capping methods.

“Our novel capping solutions improve mRNA function, help streamline manufacturing processes, and maximize capped material yield, accelerating programs from discovery to the clinic,” shared Justin Barbosa, VP and General Manager of TriLink Discovery.

Since launching the first CleanCap® analog in 2017, TriLink’s technology has continued to advance the mRNA capping industry and is used in multiple commercially approved COVID-19 vaccines. Additionally, TriLink continues to evolve and expand its innovation with the launch of the CleanCap® M6 analog, the most robust analog to date, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping method.

FUJIFILM Toyama Chemical offers development & manufacturing services from mRNA synthesis to LNP formulation in Japan. With the incorporation of nano-dispersion technology, one of the core technologies of the FUJIFILM Group, FUJIFILM Toyama Chemical has provided contract services for the design and manufacture of LNPs to a variety of customers and has accumulated experience in the production of investigational drugs.

“We are excited about our partnership with TriLink. The CleanCap technology will significantly enhance our contract mRNA synthesis services, enabling us to better serve and accelerate the mRNA drug development of our valued customers” says Akira Kase, Corporate Vice President of FUJIFILM Toyama Chemical.